Baird analyst Colleen Kusy raised the firm’s price target on Ocular Therapeutix to $12 from $10 and keeps an Outperform rating on the shares. The firm noted Ocular presented 12-month Phase 1 data for OTX-TKI in wet AMD, showing 60% of patients were rescue-free at 12 months, with evidence of disease recurrence at later timepoints, and safety was consistent and we are encouraged that partnership discussions/dataroom seem active.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on OCUL:
- Ocular Therapeutix™ Announces 12-Month Topline Data from Ongoing U.S.-Based Phase 1 Clinical Trial Evaluating OTX-TKI for Treatment of Wet AMD
- Ocular Therapeutix™ Completes Enrollment of the HELIOS Clinical Trial of OTX-TKI for the Treatment of Diabetic Retinopathy
- Ocular Therapeutix™ To Present 12-Month Top-Line Data from U.S.-Based Phase 1 Clinical Trial of OTX-TKI in Wet Age-Related Macular Degeneration at the 2023 Clinical Trials at the Summit Annual Meeting
- Ocular Therapeutix™ to Present at the Jefferies Global Healthcare Conference
- Biotech Alert: Searches spiking for these stocks today